KIT and gastrointestinal stromal tumor: Yet, some of the mutations detected in KIT-negative GISTs (including some PDGFRA mutations) are known to be imatinib sensitive; therefore, the precise diagnosis is of utmost importance and lack of immunoreactivity for KIT in a GIST should not be used as justification to deny patients therapy with imatinib.